Pharvaris reported that oral deucrictibant met all primary and secondary endpoints in a pivotal Phase 3 study as an on‑demand therapy for hereditary angioedema (HAE) attacks. The company said deucrictibant delivered rapid symptom relief with median time‑to‑response substantially faster than placebo and plans to file for FDA approval in the first half of 2026. Pharvaris positioned the pill to compete directly with KalVista’s recently approved Ekterly and noted faster median onset and shorter median time to complete symptom resolution in the trial. Management flagged an ongoing extended‑release program testing preventive dosing, with additional data expected next year. Investors and analysts are watching commercial differentiation — onset speed, durability and real‑world convenience — that could determine market share in the growing oral HAE segment. Pharvaris will use the Phase 3 dataset to inform regulatory submissions and launch planning.